Pay in 4 interest-free payments of $6.01 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
SURMOUNT-4 enrolled 783 adults without diabetes into a 36-week open-label tirzepatide lead-in
The FY26 financial performance - 29% revenue growth, 56% EBITDA growth, 109% PAT growth is impressive
This waiting period helps your body absorb the tablet better
The participants were randomly assigned in a 2:1 ratio to 68 weeks of treatment (once weekly injected semaglutide at a dose of 2.4mg) or placebo injection plus lifestyle intervention
US$ 21.37
US$ 25.89
US$ 27.16
US$ 24.69
US$ 25.26
US$ 29.35
US$ 22.10
